Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Fee Schedules Show Cuts To Physician Services

Executive Summary

US Medicare payments for services provided in physician offices will fall by nearly 4% in calendar 2022; elsewhere, the agency granted pass-through payments to three devices and maintained additional telehealth services.

You may also be interested in...



Abbott Buys CSI To Add Peripheral And Coronary Atherectomy Technologies

CSI markets minimally invasive devices to remove vascular plaques and has a full pipeline of complementary vascular intervention technologies. Abbott expects CSI’s products to complement its existing coronary intervention business and expand its presence in the peripheral market.

The Pandemic Has Reshaped Telemedicine – And ‘There’s No Going Back’

The American Telemedicine Association has formed the Government Relations Special Interest Group to further the organization’s efforts to increase access to affordable virtual health.

Telehealth Advocates Disappointed, Reenergized To Get Coverage For Older Diabetes Patients

When the US Medicare agency didn’t include diabetes telehealth coverage for its patients in a recent decision, advocates say they weren’t surprised – and now they’re even more motivated to pass legislation to achieve their goals.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT144678

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel